View in EDS HTML Full Text PDF Full Text

Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.

Saved in:
Bibliographic Details
Title: Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.
Authors: Singer, Michael1 (AUTHOR), Khanani, Arshad M.2 (AUTHOR), Wolf, Armin3 (AUTHOR), Flores, Rita4,5 (AUTHOR), Chhablani, Jay6 (AUTHOR), B, Guruprasad7 (AUTHOR), Clemens, Andreas8,9 (AUTHOR), Gedif, Kinfemichael7 (AUTHOR), Liu, Xiaoxi7 (AUTHOR), Mulyukov, Zufar8 (AUTHOR), Querques, Giuseppe10,11 (AUTHOR)
Source: Ophthalmologica. 2022, Vol. 245 Issue 4, p315-322. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:00303755
DOI:10.1159/000524245